The Surrey Clinical Research Centre was recently at the centre of an international effort with European Commission funding to design and test a vaccine to prevent HIV/AIDS. The vaccine employed several highly innovative concepts including nasal delivery to produce strong genital tract immunity, liposomal formulation, and an uniquely designed active component to make virus-blocking antibodies. The SCRC conducted the first in human clinical trial of this product, drawing on its extensive expertise in translational medicine, mucosal immunology, and Phase 1 trial accreditation. A short video was made about the EURONEUT41 project by the European Commission as part of its initiative to enhance awareness of cutting-edge EU sponsored research in high priority areas of medical need. Follow the link below:
Systemic and Mucosal Immune Responses To Sublingual Or Intramuscular Human Papilloma Virus Antigens In Healthy Female Volunteers. PLoS ONE 2012; 7(3): e33736. doi:10.1371/journal.pone.0033736.
Phase I randomised clinical trial of an HIV-1CN54, clade C, trimeric envelope vaccine candidate delivered vaginally. PLoS ONE 2011; 6(9): e25165. doi:10.1371/journal.pone.0025165.
Safety and Immunogenicity of SC599, an Oral Live Attenuated Shigella dysenteriae type-1 Vaccine in Healthy Volunteers: Results of a Phase 2, Randomized, Double-Blind Placebo-Controlled Trial. Vaccine 2009; 27: 1184–1191
Phase 1 clinical trial of live attenuated Shigella dysenteriae type-1 DeltaicsA Deltaent Deltafep DeltastxA:HgR oral vaccine SC599 in healthy human adult volunteers. Vaccine 2008; 26(7): 978—987.
Ability of SPI mutant of S. typhi to effectively induce antibody responses to the mucosal antigen enterotoxigenic E. coli heat labile toxin B subunit in humans after oral delivery. Vaccine 2007; 25(21): 4175-4182.
Induction of protective serum meningococcal bactericidal and diphtheria neutralizing antibodies, and mucosal IgA in volunteers by nasal insufflations of N. meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed with chitosan Immun 2005; 73 (12): 8256-65.
Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin IgA.
Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers. Infect Immun. 2002 Jul;70(7):3457-6.
Immune response following oral administration of cholera toxin B subunit to HIV-1 infected United Kingdom and Kenyan subjects. 1994; 8(6): 779-85.